Nintedanib Teva

Nintedanib, the active ingredient in Nintedanib Teva, is a tyrosine kinase inhibitor presented as an oral dosage form for oral use. It is indicated for idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and non‑small cell lung cancer in adult patients.

GNH USA supplies Nintedanib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nintedanib acts on multiple receptor tyrosine kinases involved in fibrotic and oncogenic pathways, providing therapeutic benefit in several serious lung conditions. - Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. - Systemic sclerosis‑associated interstitial lung disease: helps preserve lung capacity and delays worsening. - Non‑small cell lung cancer: used in combination regimens to inhibit tumor growth and angiogenesis.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Diarrhea - Nausea - Vomiting - Abdominal pain - Decreased appetite - Elevated liver enzymes (ALT/AST)

Serious or Rare Side Effects: - Hepatic failure or severe liver injury - Major bleeding events - Cardiovascular complications (e.g., myocardial infarction) - Gastrointestinal perforation - Severe infections - Pneumothorax

Patients should be monitored for safety and tolerability throughout therapy. - Liver function: assess baseline enzymes and monitor periodically. - Bleeding risk: avoid concomitant use of strong anticoagulants unless medically necessary. - Gastrointestinal health: counsel patients on managing diarrhea and report severe abdominal pain. - Cardiovascular status: evaluate history of ischemic heart disease before initiation. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Nintedanib may interact with drugs that affect its metabolism or increase bleeding risk.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase nintedanib exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce nintedanib exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding potential.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): monitor for increased side effects. - Moderate CYP3A4 inducers (e.g., phenytoin): assess therapeutic response. - Diuretics: watch renal function and electrolyte balance.